KLTO Key Statistics, Chart & Performance
The current stock price of KLTO is 0.3529 USD. In the past month the price decreased by -23.91%. In the past year, price decreased by -30.83%.
KLTO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.37 | 390.32B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.86 | 151.02B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.99 | 118.86B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.64 | 83.45B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 775.16 | 52.23B | ||
| INSM | INSMED INC | N/A | 37.11B | ||
| NTRA | NATERA INC | N/A | 32.36B | ||
| BIIB | BIOGEN INC | 11.23 | 27.57B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.44 | 20.95B | ||
| INCY | INCYTE CORP | 16.65 | 20.99B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 21.63B |
Related stock screener links
About KLTO
Company Profile
Klotho Neurosciences, Inc. engages in the provision of new therapies to treat neurodegenerative diseases. The company is headquartered in Omaha, Nebraska and currently employs 3 full-time employees. The company went IPO on 2022-04-29. The firm's licensed platforms, namely, a generic drug portfolio and a biosimilar biologics platform uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Its primary focus is the advancement of a sustainable portfolio of cell and gene therapy product candidates for age-associated neurologic diseases, both rare orphan diseases and diseases in larger patient populations. The firm's two lead gene therapy product candidates are KLTO-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and KLTO-202 (AAVmyo-Des-sKL) gene therapy product for the treatment and prevention of Lou Gehrig’s disease (amyotrophic lateral sclerosis).
Company Info
KLOTHO NEUROSCIENCES INC
13576 Walnut Street, Suite A
Omaha NEBRASKA US
Employees: 3
Phone: 18339316330
KLOTHO NEUROSCIENCES INC / KLTO FAQ
What does KLOTHO NEUROSCIENCES INC do?
Klotho Neurosciences, Inc. engages in the provision of new therapies to treat neurodegenerative diseases. The company is headquartered in Omaha, Nebraska and currently employs 3 full-time employees. The company went IPO on 2022-04-29. The firm's licensed platforms, namely, a generic drug portfolio and a biosimilar biologics platform uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Its primary focus is the advancement of a sustainable portfolio of cell and gene therapy product candidates for age-associated neurologic diseases, both rare orphan diseases and diseases in larger patient populations. The firm's two lead gene therapy product candidates are KLTO-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and KLTO-202 (AAVmyo-Des-sKL) gene therapy product for the treatment and prevention of Lou Gehrig’s disease (amyotrophic lateral sclerosis).
What is the current price of KLTO stock?
The current stock price of KLTO is 0.3529 USD. The price increased by 3.07% in the last trading session.
Does KLTO stock pay dividends?
KLTO does not pay a dividend.
What is the ChartMill rating of KLOTHO NEUROSCIENCES INC stock?
KLTO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of KLTO stock?
KLOTHO NEUROSCIENCES INC (KLTO) has a market capitalization of 25.60M USD. This makes KLTO a Nano Cap stock.
KLTO Technical Analysis
KLTO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KLTO. While KLTO has a great health rating, there are worries on its profitability.
KLTO Financial Highlights
Over the last trailing twelve months KLTO reported a non-GAAP Earnings per Share(EPS) of -0.33. The EPS decreased by -38.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -112.08% | ||
| ROE | -113.73% | ||
| Debt/Equity | 0 |